A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination

New directions in the management of advanced pancreatic cancer: a review

(2010) Caio M. Rocha-Lima   ANTI-CANCER DRUGS

Pancreatic Cancer—Could It Be that Simple? A Different Context of Vulnerability

(2009) Daniel D. Von Hoff et al.   CANCER CELL

Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy

(2009) Fernando Rivera et al.   CANCER TREATMENT REVIEWS

Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness

(2009) G. Komar et al.   CLINICAL CANCER RESEARCH

Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor

(2009) Susannah K. Leaver et al.   INTENSIVE CARE MEDICINE

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

(2009) Joanna M. Brell et al.   ONCOLOGY

Plasma Thioredoxin, a Novel Oxidative Stress Marker, in Patients with Obstructive Sleep Apnea Before and After Nasal Continuous Positive Airway Pressure

(2008) Ken-Ichi Takahashi et al.   ANTIOXIDANTS & REDOX SIGNALING

Gemcitabine in the treatment of metastatic pancreatic cancer

(2008) Andreas Hilbig et al.   Expert Review of Anticancer Therapy

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

(2008) Viviane Hess et al.   LANCET ONCOLOGY

CA 19-9 Response as an Early Indicator of the Effectiveness of Gemcitabine in Patients with Advanced Pancreatic Cancer

(2008) Yousuke Nakai et al.   ONCOLOGY